Eli Lilly (LLY) Offering Possible 13.12% Return Over the Next 14 Calendar Days

Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $182.50 short put and a strike $177.50 long put offers a potential 13.12% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $182.50 by expiration. The full premium credit of $0.58 would be kept by the premium seller. The risk of $4.42 would be incurred if the stock dropped below the $177.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 30.19 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Wed, 31 Mar 2021 12:30:00 +0000
Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top barrier to more collaboration among specialists is lack of time. This barrier is prevalent across HCP specialties with more than 80 percent of endocrinologists, cardiologists and nephrologists wishing they had the time to more closely track patients when they see multiple providers. The findings are from a survey of 1,000 U.S. healthcare professionals (i.e., primary care physicians, cardiologists, endocrinologists, nephrologists and nurse practitioners), conducted by The Harris Poll on behalf of Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), as part of the Unleashing the Truth About Diabetes and Heart Disease® campaign, which aims to increase awareness of the role of specialists in the treatment of diabetes and related chronic conditions and promote multidisciplinary collaboration.

Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?
Wed, 31 Mar 2021 11:31:00 +0000
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) have worked together for years on the development of an osteoarthritis pain drug, tanezumab. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli talked about the hurdles the two companies must jump to win U.S. approval for the drug.

Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint
Tue, 30 Mar 2021 13:01:01 +0000
Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.

Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients
Mon, 29 Mar 2021 13:32:52 +0000
Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-administered with VIR-7831 in low-risk adult patients with mild to moderate COVID-19. Results showed that bamlanivimab 700 mg co-administered with VIR-7831 500 mg demonstrated a 70% relative reduction in persistently high viral load at day seven compared to placebo, meeting the primary endpoint. Also, the treatment demonstrated a statistically significant reduction compared to placebo in the critical virologic secondary endpoints of mean change from baseline to days three, five, and seven in SARS-CoV-2 viral load. No events for the secondary endpoint of COVID-19 related hospitalization or death by day 29 in either study arm were reported. One patient (in the treatment arm) visited the emergency room for COVID-19 related symptoms. No serious adverse events were seen with the coadministration of bamlanivimab and VIR-7831. Last week, the FDA acting commissioner Janet Woodcock said that the U.S. government is not distributing Eli Lilly's bamlanivimab alone in California, Arizona, and Nevada amid prevalent COVID-19 virus variants. Price Action: LLY shares are down 0.28% at $184.8, and VIR shares are dow 1.03% at $51 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaWhite House Contemplates Waiving-Off Patent Protections For COVID-19 TreatmentsGSK Fires Moncef Slaoui Over Sexual Harassment Charges© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

UPDATE 1-Lilly-Vir's COVID-19 antibody combo reduces viral load in study
Mon, 29 Mar 2021 13:05:44 +0000
Antibody treatments from Eli Lilly and Vir Biotech reduced viral load in low-risk COVID-19 patients, results from a mid-stage trial showed on Monday. The trial is testing Lilly's bamlanivimab given in combination with Vir and partner GlaxoSmithKline's VIR-7831, the companies said. The antibodies combination demonstrated a 70% reduction in viral load at day seven compared to placebo, the companies said.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.